Sanofi licenses 5 drugs to Covis

04/8/2013 | Pharmaceutical Business Review Online · Drug Store News

Switzerland's Covis Pharma agreed to acquire the U.S. commercial rights to five drugs from Sanofi-Aventis and its units. The deal covers the prostate cancer drug Nilandron; Plaquenil, a drug for malaria, lupus and arthritis; amyotrophic lateral sclerosis drug Rilutek; Uroxatral, a drug for enlarged prostate; and high-potassium treatment Kayexalate. Sanofi keeps the products' rights elsewhere in the world.

View Full Article in:

Pharmaceutical Business Review Online · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN